OasisLMS

This activity will be of substantial interest to endocrinologists and endocrine fellows caring for individuals with or at risk of developing endocrine conditions. Additionally, the program is expected to draw interest from primary care professionals and advanced practice professionals.

Upon completion of this educational activity, learners will be able to:

• Provide a comprehensive continuing medical education meeting covering common and evolving issues in endocrinology, diabetes, and metabolism.
• Enhance the education of endocrinologists and other health professionals who treat patients with endocrine disorders.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 26.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

AMA PRA Category 1 Credits™ for the activities related to this material must be claimed by December 31, 2027. 

STATEMENT OF INDEPENDENCE 
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Clinical Endocrinology Update Steering Committee. 

DISCLOSURE POLICY 
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable. 

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The relevant financial relationships listed for these individuals has been mitigated and there are no other relevant financial relationships with ineligible companies for those with the ability to control the content for this activity.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This program is supported by unrestricted educational grants from Insulet, Medtronic, and Neurocrine Biosciences, Inc.